In addition, Imiquimod could effectively induce the production of virus-specific IgG and IgM when used as an adjuvant for inactive influenza virus vaccines, which are thought to be applicable for COVID-19 vaccine development [31,32]. Here, CD40LG is linked to COVID-19.